vs
凯勒威廉姆斯（CTO）与RECURSION PHARMACEUTICALS, INC.（RXRX）财务数据对比。点击上方公司名可切换其他公司
凯勒威廉姆斯的季度营收约是RECURSION PHARMACEUTICALS, INC.的1.2倍（$41.2M vs $35.5M），凯勒威廉姆斯净利率更高（15.1% vs -304.2%，领先319.3%），RECURSION PHARMACEUTICALS, INC.同比增速更快（681.7% vs 15.0%），过去两年RECURSION PHARMACEUTICALS, INC.的营收复合增速更高（60.5% vs 19.5%）
凯勒威廉姆斯地产是一家美国科技企业及跨国房地产特许经营商，总部位于得克萨斯州奥斯汀。截至2022年，按销售额计算，它是美国规模最大的房地产特许经营机构，业务覆盖全球多个地区。
Recursion Pharmaceuticals是一家临床阶段生物技术企业，依托人工智能技术和高通量生物实验体系，开发针对罕见病、肿瘤、炎症性疾病等领域未满足医疗需求的创新疗法，核心市场覆盖北美，与全球多家生物制药企业合作推进在研管线落地。
CTO vs RXRX — 直观对比
营收规模更大
CTO
是对方的1.2倍
$35.5M
营收增速更快
RXRX
高出666.8%
15.0%
净利率更高
CTO
高出319.3%
-304.2%
两年增速更快
RXRX
近两年复合增速
19.5%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $41.2M | $35.5M |
| 净利润 | $6.2M | $-108.1M |
| 毛利率 | — | 59.8% |
| 营业利润率 | 175.0% | -304.8% |
| 净利率 | 15.1% | -304.2% |
| 营收同比 | 15.0% | 681.7% |
| 净利润同比 | 174.4% | 39.6% |
| 每股收益（稀释后） | $0.13 | $-0.17 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTORXRX
| Q1 26 | $41.2M | — | ||
| Q4 25 | $38.3M | $35.5M | ||
| Q3 25 | $37.8M | $5.2M | ||
| Q2 25 | $37.6M | $19.2M | ||
| Q1 25 | $35.8M | $14.7M | ||
| Q4 24 | $35.7M | $4.5M | ||
| Q3 24 | $31.8M | $26.1M | ||
| Q2 24 | $28.8M | $14.4M |
净利润CTORXRX
| Q1 26 | $6.2M | — | ||
| Q4 25 | $28.3M | $-108.1M | ||
| Q3 25 | $2.9M | $-162.3M | ||
| Q2 25 | $-23.4M | $-171.9M | ||
| Q1 25 | $2.3M | $-202.5M | ||
| Q4 24 | $-15.2M | $-178.9M | ||
| Q3 24 | $6.2M | $-95.8M | ||
| Q2 24 | $1.2M | $-97.5M |
毛利率CTORXRX
| Q1 26 | — | — | ||
| Q4 25 | 75.0% | 59.8% | ||
| Q3 25 | 75.4% | -183.8% | ||
| Q2 25 | 73.0% | -4.9% | ||
| Q1 25 | 75.2% | -48.0% | ||
| Q4 24 | 74.4% | -181.4% | ||
| Q3 24 | 74.4% | 53.7% | ||
| Q2 24 | 71.1% | 36.2% |
营业利润率CTORXRX
| Q1 26 | 175.0% | — | ||
| Q4 25 | 75.1% | -304.8% | ||
| Q3 25 | 26.6% | -3327.6% | ||
| Q2 25 | -33.7% | -916.8% | ||
| Q1 25 | 22.0% | -1297.9% | ||
| Q4 24 | -20.4% | -4042.4% | ||
| Q3 24 | 15.6% | -377.1% | ||
| Q2 24 | 18.8% | -697.4% |
净利率CTORXRX
| Q1 26 | 15.1% | — | ||
| Q4 25 | 73.9% | -304.2% | ||
| Q3 25 | 7.7% | -3135.3% | ||
| Q2 25 | -62.2% | -894.2% | ||
| Q1 25 | 6.3% | -1373.3% | ||
| Q4 24 | -42.6% | -3935.5% | ||
| Q3 24 | 19.6% | -367.5% | ||
| Q2 24 | 4.1% | -676.6% |
每股收益（稀释后）CTORXRX
| Q1 26 | $0.13 | — | ||
| Q4 25 | $0.81 | $-0.17 | ||
| Q3 25 | $0.03 | $-0.36 | ||
| Q2 25 | $-0.77 | $-0.41 | ||
| Q1 25 | $0.01 | $-0.50 | ||
| Q4 24 | $-0.69 | $-0.56 | ||
| Q3 24 | $0.17 | $-0.34 | ||
| Q2 24 | $-0.03 | $-0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.3M | $743.3M |
| 总债务越低越好 | — | $9.6M |
| 股东权益账面价值 | $575.4M | $1.1B |
| 总资产 | $1.3B | $1.5B |
| 负债/权益比越低杠杆越低 | — | 0.01× |
8季度趋势，按日历期对齐
现金及短期投资CTORXRX
| Q1 26 | $8.3M | — | ||
| Q4 25 | $6.5M | $743.3M | ||
| Q3 25 | $9.3M | $659.8M | ||
| Q2 25 | $8.6M | $525.1M | ||
| Q1 25 | $8.4M | $500.5M | ||
| Q4 24 | $9.0M | $594.4M | ||
| Q3 24 | $8.2M | $427.6M | ||
| Q2 24 | $4.8M | $474.3M |
总债务CTORXRX
| Q1 26 | — | — | ||
| Q4 25 | $616.3M | $9.6M | ||
| Q3 25 | $604.2M | $11.9M | ||
| Q2 25 | $605.4M | $14.2M | ||
| Q1 25 | $602.2M | $16.4M | ||
| Q4 24 | $519.0M | $19.0M | ||
| Q3 24 | $526.8M | $20.5M | ||
| Q2 24 | $482.7M | $22.9M |
股东权益CTORXRX
| Q1 26 | $575.4M | — | ||
| Q4 25 | $567.3M | $1.1B | ||
| Q3 25 | $557.3M | $1.0B | ||
| Q2 25 | $574.1M | $919.1M | ||
| Q1 25 | $593.9M | $933.9M | ||
| Q4 24 | $612.8M | $1.0B | ||
| Q3 24 | $595.8M | $524.6M | ||
| Q2 24 | $491.8M | $584.4M |
总资产CTORXRX
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $1.5B | ||
| Q3 25 | $1.2B | $1.4B | ||
| Q2 25 | $1.2B | $1.3B | ||
| Q1 25 | $1.2B | $1.3B | ||
| Q4 24 | $1.2B | $1.4B | ||
| Q3 24 | $1.2B | $726.5M | ||
| Q2 24 | $1.0B | $775.9M |
负债/权益比CTORXRX
| Q1 26 | — | — | ||
| Q4 25 | 1.09× | 0.01× | ||
| Q3 25 | 1.08× | 0.01× | ||
| Q2 25 | 1.05× | 0.02× | ||
| Q1 25 | 1.01× | 0.02× | ||
| Q4 24 | 0.85× | 0.02× | ||
| Q3 24 | 0.88× | 0.04× | ||
| Q2 24 | 0.98× | 0.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-46.1M |
| 自由现金流经营现金流 - 资本支出 | — | $-47.3M |
| 自由现金流率自由现金流/营收 | — | -133.1% |
| 资本支出强度资本支出/营收 | — | 3.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-378.3M |
8季度趋势，按日历期对齐
经营现金流CTORXRX
| Q1 26 | — | — | ||
| Q4 25 | $64.6M | $-46.1M | ||
| Q3 25 | $25.5M | $-117.4M | ||
| Q2 25 | $21.9M | $-76.4M | ||
| Q1 25 | $10.3M | $-132.0M | ||
| Q4 24 | $59.9M | $-115.4M | ||
| Q3 24 | $21.2M | $-59.2M | ||
| Q2 24 | $12.9M | $-82.2M |
自由现金流CTORXRX
| Q1 26 | — | — | ||
| Q4 25 | — | $-47.3M | ||
| Q3 25 | — | $-117.6M | ||
| Q2 25 | — | $-79.6M | ||
| Q1 25 | — | $-133.8M | ||
| Q4 24 | — | $-116.7M | ||
| Q3 24 | — | $-63.8M | ||
| Q2 24 | — | $-83.4M |
自由现金流率CTORXRX
| Q1 26 | — | — | ||
| Q4 25 | — | -133.1% | ||
| Q3 25 | — | -2272.5% | ||
| Q2 25 | — | -413.9% | ||
| Q1 25 | — | -907.4% | ||
| Q4 24 | — | -2567.7% | ||
| Q3 24 | — | -244.6% | ||
| Q2 24 | — | -578.5% |
资本支出强度CTORXRX
| Q1 26 | — | — | ||
| Q4 25 | — | 3.5% | ||
| Q3 25 | — | 4.7% | ||
| Q2 25 | — | 16.4% | ||
| Q1 25 | — | 12.4% | ||
| Q4 24 | — | 28.6% | ||
| Q3 24 | — | 17.5% | ||
| Q2 24 | — | 8.2% |
现金转化率CTORXRX
| Q1 26 | — | — | ||
| Q4 25 | 2.28× | — | ||
| Q3 25 | 8.75× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 4.56× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.40× | — | ||
| Q2 24 | 10.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
